Waldenstrom Macroglobulinemia
Information
- Disease name
- Waldenstrom Macroglobulinemia
- Disease ID
- Description
Disease area statistics
[No Data.]
Chromosome band
[No Data.]
Annotation
| Genes | Mutation | Description | Source | Links |
|---|
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT04450069 | Active, not recruiting | Phase 1 | CLBR001 and SWI019 in Patients With Relapsed / Refractory B-cell Malignancies | August 14, 2020 | June 2024 |
| NCT05024045 | Active, not recruiting | Phase 1 | Study of Oral LOXO-338 in Patients With Advanced Blood Cancers | September 30, 2021 | December 2024 |
| NCT03506373 | Active, not recruiting | Phase 2 | Ibrutinib and Ixazomib Citrate in Treating Newly Diagnosed, Relapsed or Refractory Waldenstrom Macroglobulinemia | July 5, 2018 | May 1, 2025 |
| NCT04273139 | Active, not recruiting | Phase 2 | Ibrutinib + Venetoclax in Untreated WM | July 9, 2020 | February 1, 2028 |
| NCT01479842 | Active, not recruiting | Phase 1 | Rituxan/Bendamustine/PCI-32765 in Relapsed DLBCL, MCL, or Indolent Non-Hodgkin's Lymphoma | December 7, 2011 | December 31, 2024 |
| NCT03521596 | Active, not recruiting | Non-invasive Diagnostics and Monitoring of MRD and Clonal Evolution in Waldenström's Macroglobulinemia and in IgM-MGUS | August 28, 2018 | October 2025 | |
| NCT02339922 | Active, not recruiting | Phase 2 | Ixazomib Citrate and Rituximab in Treating Patients With Indolent B-cell Non-Hodgkin Lymphoma | May 19, 2016 | January 6, 2031 |
| NCT03620903 | Active, not recruiting | Phase 2 | Efficacy of First Line B-RI for Treatment Naive Waldenström's Macroglobulinemia | September 11, 2019 | September 2029 |
| NCT04464200 | Active, not recruiting | Phase 1 | 19(T2)28z1xx Chimeric Antigen Receptor (CAR) T Cells in People With B-Cell Cancers | July 6, 2020 | July 2026 |
| NCT00039676 | Active, not recruiting | Clinical, Laboratory and Epidemiologic Characterization of Individuals and Families at High Risk of Hematologic Cancer | July 8, 2002 | ||
| NCT04018248 | Active, not recruiting | Phase 1 | BR101801 in Adult Patients With Advanced Hematologic Malignancies( Phase I) | April 21, 2020 | March 2024 |
| NCT03333486 | Active, not recruiting | Phase 2 | Fludarabine Phosphate, Cyclophosphamide, Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Blood Cancer | December 7, 2017 | August 28, 2024 |
| NCT03740529 | Active, not recruiting | Phase 1/Phase 2 | A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL | November 16, 2018 | January 2028 |
| NCT03133221 | Active, not recruiting | Phase 2 | 1630GCC: Zydelig Maintenance in B-Cell Non-Hodgkin's Lymphoma After Autologous Stem Cell Transplantation | October 23, 2017 | March 2025 |
| NCT03162536 | Active, not recruiting | Phase 1/Phase 2 | A Study of Nemtabrutinib (MK-1026) in Participants With Relapsed or Refractory Hematologic Malignancies (ARQ 531-101/MK-1026-001) | June 26, 2017 | September 12, 2025 |
| NCT03192397 | Active, not recruiting | Phase 1/Phase 2 | Chemotherapy, Total Body Irradiation, and Post-Transplant Cyclophosphamide in Reducing Rates of Graft Versus Host Disease in Patients With Hematologic Malignancies Undergoing Donor Stem Cell Transplant | August 9, 2017 | May 21, 2027 |
| NCT05172700 | Available | Expanded Access Program for Pirtobrutinib for Participants With B-Cell Cancer | |||
| NCT01075321 | Completed | Phase 1/Phase 2 | Everolimus and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma | January 10, 2011 | February 13, 2020 |
| NCT01076543 | Completed | Phase 1/Phase 2 | Lenalidomide and Temsirolimus in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma | April 15, 2010 | September 30, 2018 |
| NCT01093586 | Completed | Phase 2 | Donor Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies | September 2007 | December 2015 |
| NCT01109069 | Completed | Phase 2 | Safety and Tolerability Study of PCI-32765 in B Cell Lymphoma and Chronic Lymphocytic Leukemia | June 2010 | April 26, 2019 |
| NCT01118689 | Completed | Phase 1 | Dose Escalation Study of MLN0128 in Relapsed or Refractory Multiple Myeloma or Waldenstrom Macroglobulinemia | November 2010 | July 2013 |
| NCT01129193 | Completed | Phase 1 | AR-42 in Treating Patients With Advanced or Relapsed Multiple Myeloma, Chronic Lymphocytic Leukemia, or Lymphoma | May 4, 2010 | January 7, 2017 |
| NCT01177371 | Completed | Phase 2 | High-Dose Busulfan and High-Dose Cyclophosphamide Followed By Donor Bone Marrow Transplant in Treating Patients With Leukemia, Myelodysplastic Syndrome, Multiple Myeloma, or Recurrent Hodgkin or Non-Hodgkin Lymphoma | March 1988 | February 2010 |
| NCT01199562 | Completed | Infection Prophylaxis and Management in Treating Cytomegalovirus (CMV) Infection in Patients With Hematologic Malignancies Previously Treated With Donor Stem Cell Transplant | December 2010 | December 2013 | |
| NCT01231412 | Completed | Phase 3 | Graft-Versus-Host Disease Prophylaxis in Treating Patients With Hematologic Malignancies Undergoing Unrelated Donor Peripheral Blood Stem Cell Transplant | November 2010 | June 30, 2017 |
| NCT01251575 | Completed | Phase 2 | Sirolimus, Cyclosporine, and Mycophenolate Mofetil in Preventing Graft-versus-Host Disease in Treating Patients With Blood Cancer Undergoing Donor Peripheral Blood Stem Cell Transplant | December 1, 2010 | February 11, 2019 |
| NCT01254578 | Completed | Phase 1 | Lenalidomide After Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancers | November 24, 2010 | November 9, 2012 |
| NCT01261247 | Completed | Phase 2 | Panobinostat in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma | January 17, 2011 | December 2, 2019 |
| NCT01272817 | Completed | N/A | Nonmyeloablative Allogeneic Transplant | October 2001 | October 2015 |
| NCT01273766 | Completed | Phase 2 | Deferasirox in Treating Iron Overload Caused By Blood Transfusions in Patients With Hematologic Malignancies | January 2011 | December 2014 |
| NCT01326702 | Completed | Phase 1/Phase 2 | Veliparib, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory Lymphoma, Multiple Myeloma, or Solid Tumors | July 2011 | April 2015 |
| NCT01351935 | Completed | Phase 1 | Escalating Dose Study in Subjects With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, and Waldenstrom's Macroglobulinemia | July 18, 2011 | June 26, 2015 |
| NCT01523223 | Completed | Phase 1 | Donor Peripheral Stem Cell Transplant in Treating Patients With Hematolymphoid Malignancies | January 2012 | October 2016 |
| NCT01527045 | Completed | Phase 2 | Donor Atorvastatin Treatment in Preventing Severe Acute GVHD After Nonmyeloablative Peripheral Blood Stem Cell Transplant in Patients With Hematological Malignancies | September 25, 2012 | April 2019 |
| NCT03833180 | Completed | Phase 1 | A Study of Zilovertamab Vedotin (MK-2140) (VLS-101) in Participants With Hematologic Malignancies (MK-2140-001) | March 14, 2019 | December 18, 2023 |
| NCT01567709 | Completed | Phase 1 | Alisertib in Combination With Vorinostat in Treating Patients With Relapsed or Recurrent Hodgkin Lymphoma, B-Cell Non-Hodgkin Lymphoma, or Peripheral T-Cell Lymphoma | April 16, 2012 | March 29, 2018 |
| NCT01813227 | Completed | Phase 2 | A Phase II Study of Carfilzomib in Relapsed Waldenström's Macroglobulinemia (WM) IST-CAR-531 | April 2013 | October 2018 |
| NCT02257242 | Completed | Phase 1 | Vincristine Sulfate Liposome Injection (Marqibo®), Bendamustine and Rituximab-Phase I Trial in Indolent B-cell Lymphoma | May 10, 2017 | November 18, 2020 |
| NCT00072514 | Completed | Phase 2 | Gemcitabine Hydrochloride, Carboplatin, Dexamethasone, and Rituximab in Treating Patients With Previously Treated Lymphoid Malignancies | August 2003 | November 2013 |
| NCT02302469 | Completed | Phase 1/Phase 2 | Study of Lenalidomide in Relapse/Refractory Waldenstrom Macroglobulinemia | March 2009 | April 2017 |
| NCT02332980 | Completed | Phase 2 | Pembrolizumab Alone or With Idelalisib or Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Other Low-Grade B-Cell Non-Hodgkin Lymphomas | February 19, 2015 | January 4, 2022 |
| NCT02669017 | Completed | Phase 1 | Study of ADCT-402 in Patients With Relapsed or Refractory B-cell Lineage Non Hodgkin Lymphoma (B-NHL) | March 2016 | February 21, 2019 |
| NCT02677324 | Completed | Phase 2 | Study of ABT-199 (GDC-199) In Patients With Relapsed Or Refractory Waldenström Macroglobulinemia | May 9, 2016 | February 7, 2022 |
| NCT02916979 | Completed | Phase 1 | Myeloid-Derived Suppressor Cells and Checkpoint Immune Regulators' Expression in Allogeneic SCT Using FluBuATG | September 6, 2016 | February 11, 2022 |
| NCT00075478 | Completed | Phase 3 | Total-Body Irradiation With or Without Fludarabine Phosphate Followed By Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer | October 2003 | February 2, 2014 |
| NCT02962401 | Completed | Phase 2 | Efficacity of Idelalisib and Obinutuzumab in Patient With Relapsed Refractory Waldenstrom's Macroglobulinemia | March 7, 2017 | April 13, 2023 |
| NCT04062448 | Completed | Phase 2 | A Study of Ibrutinib in Combination With Rituximab, in Japanese Participants With Waldenstrom's Macroglobulinemia (WM) | September 25, 2019 | March 2, 2023 |
| NCT04042376 | Completed | Phase 4 | A Study of Ibrutinib (PCI-32765) in Chinese Participants With Relapse or Refractory Waldenstrom's Macroglobulinemia (WM) | December 18, 2019 | March 19, 2024 |
| NCT01529827 | Completed | Phase 2 | Fludarabine Phosphate, Melphalan, and Low-Dose Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies | February 28, 2012 | August 29, 2019 |
| NCT03630042 | Completed | Phase 2 | Investigating the Safety and Efficacy of Rituximab and Pembrolizumab in Relapsed/Refractory Waldenström's Macroglobulinaemia | September 6, 2019 | June 1, 2023 |
| NCT00082784 | Completed | Phase 1 | Bortezomib and Flavopiridol in Treating Patients With Recurrent or Refractory Indolent B-Cell Neoplasms | March 2004 | September 2014 |
| NCT00083707 | Completed | Phase 2 | Anti-Angiogenesis Therapy Using Thalidomide in Patients With Waldenstrom's Macroglobulinemia | January 1999 | February 2003 |
| NCT00096161 | Completed | Phase 2 | Pentostatin and Lymphocyte Infusion in Preventing Graft Rejection in Patients Who Have Undergone Donor Stem Cell Transplant | May 2003 | August 2015 |
| NCT00105001 | Completed | Phase 2 | Tacrolimus and Mycophenolate Mofetil With or Without Sirolimus in Preventing Acute Graft-Versus-Host Disease in Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer | November 2004 | May 8, 2015 |
| NCT06084650 | Completed | Optical Coherence Tomography (OCT) and OCT Angiography(OCTA) Deep Learning in Waldenström's Macroglobulinemia Patients | January 1, 2023 | October 1, 2023 | |
| NCT00244855 | Completed | Phase 2 | Rituximab and Dexamethasone in Treating Patients With Low-Grade Non-Hodgkin Lymphoma | May 2004 | August 29, 2011 |
| NCT00438880 | Completed | Phase 1/Phase 2 | Agatolimod Sodium, Rituximab, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Recurrent or Refractory Non-Hodgkin Lymphoma | October 2004 | November 2014 |
| NCT00608361 | Completed | Phase 1 | Dasatinib in Treating Patients With Solid Tumors or Lymphomas That Are Metastatic or Cannot Be Removed By Surgery | October 2008 | August 2014 |
| NCT00711828 | Completed | Phase 2 | Rituximab, Cyclophosphamide, Bortezomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Low-Grade Follicular Lymphoma, Waldenstrom Macroglobulinemia, or Mantle Cell Lymphoma | August 2008 | April 6, 2018 |
| NCT00720135 | Completed | Phase 1 | Fusion Protein Cytokine Therapy After Rituximab in Treating Patients With B-Cell Non-Hodgkin Lymphoma | January 2008 | July 2014 |
| NCT00777738 | Completed | Phase 2 | Efficacy of Bortezomib (Velcade(R)) in Patients With Advanced Waldenström Macroglobulinemia | October 2008 | August 2012 |
| NCT00783367 | Completed | Phase 2 | Combination Therapy Using Lenalidomide (Revlimid)- Low Dose Dexamethasone and Rituximab for Treatment of Rituximab-Resistant, Non-Aggressive B-Cell Lymphomas | July 2008 | November 23, 2020 |
| NCT00789776 | Completed | Phase 1/Phase 2 | Fludarabine Phosphate, Cyclophosphamide, Total-Body Irradiation, and Donor Bone Marrow Transplant Followed by Donor Natural Killer Cell Therapy, Mycophenolate Mofetil, and Tacrolimus in Treating Patients With Hematologic Cancer | October 13, 2008 | May 2017 |
| NCT00861510 | Completed | Phase 1 | A Pilot Study of the Safety and Activity of Escalating Doses of ON 01910.Na in Patients With Relapsed Mantle Cell Lymphoma, Multiple Myeloma, Chronic Lymphocytic Leukemia, and Related Lymphoid Malignancies | March 5, 2009 | October 19, 2012 |
| NCT01008462 | Completed | Phase 2 | Autologous Peripheral Blood Stem Cell Transplant Followed by Donor Bone Marrow Transplant in Treating Patients With High-Risk Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Multiple Myeloma, or Chronic Lymphocytic Leukemia | March 18, 2010 | June 30, 2018 |
| NCT03364231 | Completed | Phase 2 | Study to Assess the Efficacy and Safety of Umbralisib in Participants With Non-Follicular Indolent Non-Hodgkin's Lymphoma | November 30, 2017 | February 15, 2022 |
| NCT04488354 | Enrolling by invitation | Phase 1 | Long-term Follow-up Study for Patients Treated With CLBR001 CAR-T | January 21, 2021 | August 2036 |
| NCT01804686 | Enrolling by invitation | Phase 3 | A Long-term Extension Study of PCI-32765 (Ibrutinib) | September 9, 2013 | January 29, 2027 |
| NCT05099471 | Not yet recruiting | Phase 2 | Efficacy of Venetoclax in Combination With Rituximab in Waldenström's Macroglobulinemia | September 2024 | October 2032 |
| NCT04702932 | Not yet recruiting | Establishment of Genomic, Transcriptomic and Functional Characteristics of Tumor Cells in Hyperinflammatory Hemopathies | September 1, 2021 | September 1, 2036 | |
| NCT06340737 | Recruiting | Phase 1 | AutologousCD22 Chimeric Antigen Receptor (CAR)T Cells in w/Recurrent/Refractory B Cell Lymphomas | March 29, 2024 | April 2031 |
| NCT00923507 | Recruiting | Natural History Study of Monoclonal B Cell Lymphocytosis (MBL), Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL), Lymphoplasmacytic Lymphoma (LPL)/Waldenstrom Macroglobulinemia (WM), and Splenic Marginal Zone Lymphoma (SMZL) | May 29, 2008 | ||
| NCT02269592 | Recruiting | Study of MGUS, Smoldering Myeloma, Early MDS and CLL to Assess Molecular Events of Progression and Clinical Outcome | August 2014 | September 2030 | |
| NCT02952508 | Recruiting | Phase 2 | Study of Iopofosine I 131 (CLR 131) in Select B-Cell Malignancies (CLOVER-1) and Pivotal Expansion in Waldenstrom Macroglobulinemia | July 26, 2017 | June 30, 2025 |
| NCT03820817 | Recruiting | Phase 1 | Rifaximin in Patients With Monoclonal Gammopathy | May 15, 2019 | November 30, 2025 |
| NCT04028479 | Recruiting | The Registry of Oncology Outcomes Associated With Testing and Treatment | May 5, 2021 | October 1, 2031 | |
| NCT04061512 | Recruiting | Phase 2/Phase 3 | Rituximab and Ibrutinib (RI) Versus Dexamethasone, Rituximab and Cyclophosphamide (DRC) as Initial Therapy for Waldenström's Macroglobulinaemia | February 3, 2020 | March 2030 |
| NCT04072458 | Recruiting | Phase 1 | A Clinical Trial of BP1002 in Patients With Advanced Lymphoid Malignancies | November 5, 2020 | January 2026 |
| NCT04116437 | Recruiting | Phase 2 | Zanubrutinib (BGB-3111) in Participants With Previously Treated B-Cell Lymphoma Intolerant of Prior Bruton Tyrosine Kinase Inhibitor (BTKi) Treatment | October 15, 2019 | October 2025 |
| NCT04260217 | Recruiting | Phase 1 | APG-2575 Single Agent or in Combination With Ibrutinib or Rituximab in Patients With Waldenström Macroglobulinemia | May 30, 2021 | December 30, 2025 |
| NCT04263480 | Recruiting | Phase 2 | Efficacy and Safety of Carfilzomib in Combination With Ibrutinib vs Ibrutinib in Waldenström's Macroglobulinemia | February 18, 2021 | February 2028 |
| NCT04624906 | Recruiting | Phase 2 | Bendamustine, Rituximab and Acalabrutinib in Waldenstrom's Macroglobulinemia | March 2, 2021 | March 2030 |
| NCT04775745 | Recruiting | Phase 1 | Study of Oral Administration of LP-168 in Patients With Relapsed or Refractory B-cell Malignancies. | July 19, 2021 | December 31, 2025 |
| NCT04840602 | Recruiting | Phase 2 | Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib and Rituximab) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma | January 5, 2022 | March 31, 2028 |
| NCT04898647 | Recruiting | N/A | Clinical Study of the Hyperviscosity Syndrome in Waldenström Macroglobulinemia | May 14, 2021 | August 2024 |
| NCT05020678 | Recruiting | Phase 1 | NKX019, Intravenous Allogeneic Chimeric Antigen Receptor Natural Killer Cells (CAR NK), in Adults With B-cell Cancers | August 20, 2021 | December 2038 |
| NCT05065554 | Recruiting | Phase 2 | ACALA-R In Predominantly Demyelinating IgM Mediated Neuropathy | November 16, 2021 | October 1, 2028 |
| NCT05093153 | Recruiting | Spanish Registry of Patients With IgM Monoclonal Gammopathies | October 1, 2021 | March 31, 2025 | |
| NCT05190705 | Recruiting | Phase 2 | Loncastuximab Tesirine in WM | February 17, 2022 | August 1, 2027 |
| NCT05544019 | Recruiting | Phase 1 | Study of SGR-1505 in Mature B-Cell Neoplasms | April 10, 2023 | March 2026 |
| NCT05602363 | Recruiting | Phase 1 | AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma | August 1, 2023 | September 2027 |
| NCT05640102 | Recruiting | Observational Study Evaluating the Efficacy and Safety of Zanubrutinib in Participants With Waldenström Macroglobulinemia | March 3, 2023 | December 2027 | |
| NCT05734495 | Recruiting | Phase 2 | Pirtobrutinib and Venetoclax in Waldenström Macroglobulinemia | May 2, 2023 | January 25, 2033 |
| NCT05914662 | Recruiting | Phase 2 | Zanubrutinib Plus BR in Newly Diagnosed Symptomatic WM | February 15, 2023 | December 15, 2025 |
| NCT05952037 | Recruiting | Phase 2 | Study to Evaluate the Efficacy and Safety of BGB-11417 in Participants With Waldenström's Macroglobulinemia | September 28, 2023 | September 2028 |
| NCT06151730 | Recruiting | Evaluation of Hypertension Management and Cardiovascular Adverse Event Prevention in Patients With B-cell Malignancies Undergoing Treatment With Bruton Tyrosine Kinase Inhibitors, the HALT Study | January 5, 2024 | December 1, 2025 | |
| NCT01416428 | Terminated | Phase 1/Phase 2 | Open-label Study of the Safety and Activity of Oprozomib in Patients With Hematologic Malignancies | October 15, 2011 | August 12, 2019 |
| NCT03679624 | Terminated | Phase 2 | Daratumumab Plus Ibrutinib in Patients With Waldenstrӧm's Macroglobulinemia | July 30, 2020 | October 13, 2020 |
| NCT01045928 | Terminated | Phase 1 | Lenalidomide And Rituximab as Maintenance Therapy in Treating Patients With B-Cell Non-Hodgkin Lymphoma | January 2010 | March 2012 |
| NCT03269552 | Terminated | Phase 2 | Carfilzomib With or Without Rituximab in the Treatment of Waldenstrom Macroglobulinemia or Marginal Zone Lymphoma | December 18, 2017 | December 28, 2018 |
| NCT03037645 | Terminated | Phase 1/Phase 2 | Safety, PK, PD, and Antitumor Activity of Vecabrutinib (SNS-062) in B Lymphoid Cancers | April 28, 2017 | August 31, 2020 |
| NCT00113802 | Terminated | Phase 2 | Study of Epratuzumab (hLL2) in Patients With Waldenstrom's Macroglobulinemia | August 2004 | December 2006 |
| NCT04115059 | Terminated | Phase 1 | Dasatinib In Waldenström Macroglobulinemia | November 4, 2019 | December 31, 2021 |
| NCT01116154 | Terminated | Phase 1 | Vorinostat and Lenalidomide in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma | May 2010 | August 2010 |
| NCT02109224 | Terminated | Phase 1 | Ibrutinib in Treating Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma in Patients With HIV Infection | September 2014 | July 2015 |
| NCT02086591 | Terminated | Phase 2 | A Phase II Study of Doxycycline in Relapsed NHL | March 2014 | November 2015 |
| NCT01779167 | Terminated | Phase 2 | Thalidomide, Lenalidomide, and Rituximab for Previously Treated Waldenstrom Macroglobulinemia | June 2012 | April 2014 |
| NCT00107614 | Terminated | Phase 2 | DT PACE, Tandem Autologous Transplant, Maintenance Therapy for Waldenstrom's Macroglobulinemia Patients | November 2002 | February 2008 |
| NCT03601819 | Terminated | Phase 1 | Pacritinib in Relapsed/Refractory Lymphoproliferative Disorders | May 15, 2019 | July 17, 2020 |
| NCT03335098 | Unknown status | Phase 2 | Study of VTD in Waldenstrom's Macroglobulinemia | November 21, 2016 | December 2020 |
| NCT05003141 | Unknown status | Phase 1 | PSB202 in Patients With Previously Treated-, Relapsed-, Indolent B-Cell Malignancies | November 15, 2021 | January 2024 |
| NCT04830046 | Unknown status | Covid-19 Vaccine Responsiveness in MM and Waldenstrom | September 2021 | August 1, 2022 | |
| NCT03679455 | Unknown status | Phase 2 | A Study of Obinutuzumab (RO5072759) Induction in Patients With Relapsed/ Refractory Waldenström Macroglobulinemia, OBI-1 | September 21, 2018 | December 2022 |
| NCT04893564 | Withdrawn | N/A | Prognostic Value of Circulating Tumoral DNA After the First 6 Months of Treatment in Patients With Waldenström Macroglobulinemia | May 14, 2021 | May 2024 |
| NCT00003512 | Withdrawn | Phase 2 | Antineoplaston Therapy in Treating Patients With Recurrent or Refractory Waldenstrom's Macroglobulinemia | February 18, 1999 | April 26, 2000 |
| NCT02298816 | Withdrawn | B-Cell Hematologic Malignancy Vaccination Registry | August 2014 | December 2025 | |
| NCT04665115 | Withdrawn | Phase 2 | Ibrutinib for the Treatment of Patients With B-Cell Malignancies Who Are Infected With Coronavirus Disease 2019 (COVID-19) | November 23, 2020 | July 22, 2022 |
| NCT05176691 | Withdrawn | Phase 1 | HMPL-760 Safety and Tolerability Study in Patients With Previously Treated CLL/SLL or NHL | February 15, 2022 | November 16, 2022 |
| NCT04043845 | Withdrawn | Phase 1 | ERK 1/2 Signaling in Ibrutinib Resistant B-cell Malignancies | February 3, 2020 | February 3, 2020 |
- MedGen concept unique identifier (MedGen Concept name)
- C1835192
- MedGen unique identifier (MedGen Concept name)
- 320546
- MeSH unique ID (MeSH (Medical Subject Headings))
- D008258